I have fantastic news to share today!
We started this journey 6 years ago at Rubedo Life Sciences on the mission to develop a new generation of therapies for age-related diseases targeting cellular senesce biology, with the potential to extend healthy life span as part of the emerging field of Longevity Medicine. The idea became quickly a proof of concept for making novel selective molecules that can target specific senescent cell types. That was the foundation for our discovery platform Alembic®, a single-cell-multi-Omics platform designed to untangle the heterogeneity of pathologic cells emerging in chronic diseases in human tissues and learn their vulnerabilities. Today we have a therapeutic pipeline with multiple programs including in chronic lung diseases, also funded by California Institute for Regenerative Medicine (CIRM). Our lead program in chronic inflammatory skin diseases and skin aging partnered with Beiersdorf to develop a new generation of anti-aging products for skincare parallel to our therapeutics for skin diseases. We are now moving this program into the clinic for a First-in-human study in patients to assess the effects on skin diseases and skin aging biology of our development candidate First-in-Class RLS-1496 and its safety.
I am incredibly proud for what the team have accomplished so far and where we are. Today I am really excited to announce that I am passing the baton of the CEO role to an amazing rockstar executive who is joining forces with me and the rest of the team to bring Rubedo into the clinic and its next stage of growth. Welcome Frederick Beddingfield MD, PhD!
While I will continue operating side-by-side with the new CEO on corporate operations, I will re-focus my expertise into R&D operations and innovation, continuing leveraging our platform and pipeline and supporting Rubedo in its next stage of growth.
Dr. Beddingfield MD PhD, a physician-scientist, serial biotech entrepreneur, and brings more than 20 years of life sciences leadership to Rubedo. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017, and previously served as Chief Medical Officer at Kythera Biopharmaceuticals, which was acquired by Allergan for $2.1 billion.
His tenure at Allergan spans more than a decade, where he held multiple senior roles, including Therapeutic Area Head of Dermatology and Chief Medical Officer of Allergan Medical. He led the development and approvals of globally recognized brands across medical dermatology, aesthetics, neurology, and metabolic therapies. These brands include Botox® (for cosmetic, hyperhidrosis, and spasticity indications), Juvederm®, Voluma®, Kybella®, Latisse®, Aczone®, and Tazorac®. He was most recently executive partner at Apollo Health Ventures, focusing on biotech start-ups in longevity and age-related diseases. Prior to Apollo, he was the former CEO and director of Kira Pharmaceuticals.
Ad Maiora!
